Pfizer's Diversified Drug Portfolio Fuels Growth as COVID Sales Decline
Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways.
Pfizer made more money than expected and is selling lots of different medicines, not just COVID shots. When a company sells many kinds of products, it's usually safer because it doesn't rely on one thing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.